Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 13/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27331978 | 0.96 | NOD1 (0.37) | NOD1TP53SMN1; SMN2FOLH1DPP7 | |
| SCHEMBL29300537 | 0.93 | NOD1 (0.36) | NOD1TP53SMN1; SMN2FOLH1LTA4H | |
| SCHEMBL29299665 | 0.87 | DPP7 (0.43) | NOD1TP53SMN1; SMN2FOLH1DPP7 | |
| SCHEMBL27331646 | 0.86 | ALDH1A1 (0.39) | TP53SMN1; SMN2FOLH1ALBSIGMAR1 | |
| SCHEMBL29299811 | 0.85 | DPP7 (0.45) | NOD1TP53SMN1; SMN2FOLH1DPP7 | |
| SCHEMBL29299824 | 0.84 | DPP7 (0.43) | NOD1TP53SMN1; SMN2FOLH1DPP7 | |
| SCHEMBL29299797 | 0.84 | DPP7 (0.46) | NOD1TP53SMN1; SMN2FOLH1DPP7 | |
| SCHEMBL29299624 | 0.82 | DPP7 (0.40) | NOD1LTA4HDPP7 | |
| SCHEMBL29299588 | 0.81 | DPP7 (0.39) | NOD1LTA4HDPP7 | |
| SCHEMBL29299590 | 0.81 | DPP7 (0.39) | NOD1LTA4HDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | NOD1 4013/4885TP53 517/4885SMN1; SMN2 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.